DOI QR코드

DOI QR Code

Prognostic Significance of C-reactive Protein in Urological Cancers: a Systematic Review and Meta-analysis

  • Dai, Jin ;
  • Tang, Kun ;
  • Xiao, Wei ;
  • Yu, Gan ;
  • Zeng, Jin ;
  • Li, Wei ;
  • Zhang, Ya-Qun ;
  • Xu, Hua ;
  • Chen, Zhi-Qiang ;
  • Ye, Zhang-Qun
  • Published : 2014.04.30

Abstract

Background: C-reactive protein (CRP), considered as a prototypical inflammatory cytokine, has been proposed to be involved in tumor progression through inflammation. Recent studies have indicated CRP as a progostic predictor for urological cancers, but the results remain controversial. Materials and Methods: A systematic search of Medline, Scopus and the Cochrane Library was performed to identify eligible studies published between Jan 1, 2001 and Sep 1, 2013. Outcomes of interest were collected from studies comparing overall survival (OS), cancer-specific survival (CSS) and relapse-free survival (RFS) in patients with elevated CRP levels and those having lower levels. Studies were pooled, and combined hazard ratio (HR) of CRP with its 95% confidence interval (CI) for survival were used for the effect size estimate. Results: A total of 43 studies (7,490 patients) were included in this meta-analysis (25 for RCC, 10 for UC, and 8 for PC). Our pooled results showed that elevated serum CRP level was associated with poor OS (HR: 1.26, 95%CI: 1.22-1.30) and RFS (HR: 1.38 95%CI: 1.29-1.47), respectively. For CSS the pooled HR (HR: 1.33, 95%CI: 1.28-1.39) for higher CRP expression could strongly predict poorer survival in urological cancers. Simultaneously, elevated serum CRP was also significantly associated with poor prognosis in the subgroup analysis. Conclusions: Our pooled results demonstrate that a high serum level of CRP as an inflammation biomarker denotes a poor prognosis of patients with urological cancers. Further large prospective studies should be performed to confirm whether CRP, as a biomarker of inflammation, has a prognostic role in urological cancer progression.

Keywords

C-reactive protein;prognosis;urological cancer;meta-analysis

References

  1. Wu Y, Fu X, Zhu X, et al (2011). Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 137, 887-96. https://doi.org/10.1007/s00432-010-0951-3
  2. Yasuda Y, Saito K, Yuasa T, et al (2013). Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol, 18, 884-9. https://doi.org/10.1007/s10147-012-0454-0
  3. Yoshida S, Saito K, Koga F, et al (2008). C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int, 101, 978-81. https://doi.org/10.1111/j.1464-410X.2007.07408.x
  4. Yu Q, Yu XF, Zhang SD, et al (2013). Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 5735-40. https://doi.org/10.7314/APJCP.2013.14.10.5735
  5. Stein B, Schrader AJ, Wegener G, et al (2013). Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC Cancer, 13, 101. https://doi.org/10.1186/1471-2407-13-101
  6. Saito K, Kihara K (2011). C-reactive protein as a biomarker for urological cancers. Nat Rev Urol, 8, 659-66.
  7. Steffens S, Kohler A, Rudolph R, et al (2012). Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer, 12, 399. https://doi.org/10.1186/1471-2407-12-399
  8. Saito K, Kihara K (2013). Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol, 20, 161-71. https://doi.org/10.1111/j.1442-2042.2012.03121.x
  9. Tanaka M, Fujimoto K, Okajima E, et al (2008). Prognostic factors of renal cell carcinoma with extension into inferior vena cava. Int J Urol, 15, 394-8. https://doi.org/10.1111/j.1442-2042.2008.02017.x
  10. Sim SH, Messenger MP, Gregory WM, et al (2012). Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer, 107, 1131-7. https://doi.org/10.1038/bjc.2012.360
  11. Tanaka N, Kikuchi E, Shirotake S, et al (2012). The predictive value of c-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional Study. Eur Urol, 65, 227-34.
  12. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  13. Van Hemelrijck M, Jungner I, Walldius G, et al (2011). Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer, 129, 1485-92. https://doi.org/10.1002/ijc.25773
  14. Vogl UM, Zehetgruber H, Dominkus M, et al (2006). Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer, 95, 691-8. https://doi.org/10.1038/sj.bjc.6603327
  15. Parmar MK, Torri V and Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  16. Pond GR, Armstrong AJ, Wood BA, et al (2012). Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int, 110, 461-8. https://doi.org/10.1111/j.1464-410X.2012.11148.x
  17. Obata J, Kikuchi E, Tanaka N, et al (2012). C-reactive protein: A biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy. Urol Oncol.
  18. Prins RC, Rademacher BL, Mongoue-Tchokote S, et al (2012). C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC):confirmatory results. Urol Oncol, 30, 33-7. https://doi.org/10.1016/j.urolonc.2009.11.012
  19. Ramsey S, Lamb GW, Aitchison M, et al (2007). Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer, 109, 205-12. https://doi.org/10.1002/cncr.22400
  20. Peccatori J, Barkholt L, Demirer T, et al (2005). Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer, 104, 2099-103. https://doi.org/10.1002/cncr.21477
  21. Ramsey S, Lamb GW, Aitchison M, McMillan DC (2008). Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int, 101, 959-63. https://doi.org/10.1111/j.1464-410X.2007.07363.x
  22. Saito K, Kawakami S, Ohtsuka Y, et al (2007). The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int, 100, 269-73. https://doi.org/10.1111/j.1464-410X.2007.06934.x
  23. Saito K, Kihara K (2010). Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev Anticancer Ther, 10, 1979-89. https://doi.org/10.1586/era.10.192
  24. Lamb GW, McMillan DC, Ramsey S, Aitchison M (2006). The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer, 94, 781-4. https://doi.org/10.1038/sj.bjc.6603034
  25. Mantovani A, Allavena P, Sica A and Balkwill F (2008). Cancerrelated inflammation. Nature, 454, 36-44.
  26. McArdle PA, Mir K, Almushatat AS, et al (2006). Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int, 77, 127-9. https://doi.org/10.1159/000093905
  27. Komai Y, Saito K, Sakai K, Morimoto S (2007). Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int, 99, 77-80. https://doi.org/10.1111/j.1464-410X.2006.06497.x
  28. Lehrer S, Diamond EJ, Mamkine B, et al (2005). C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int, 95, 961-2. https://doi.org/10.1111/j.1464-410X.2005.05447.x
  29. McArdle PA, Qayyum T and McMillan DC (2010). Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up. Urol Int, 84, 430-5. https://doi.org/10.1159/000313364
  30. Miyake H, Kurahashi T, Takenaka A, et al (2009). Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol, 27, 598-603. https://doi.org/10.1016/j.urolonc.2008.07.023
  31. Miyake H, Sakai I, Muramaki M, et al (2009). Prediction of response to combined immunotherapy with interferonalpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int J Urol, 16, 465-71. https://doi.org/10.1111/j.1442-2042.2009.02289.x
  32. Nakashima J, Kikuchi E, Miyajima A, et al (2008). Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol Int, 80, 129-33. https://doi.org/10.1159/000112601
  33. Ito K, Yoshii H, Sato A, et al (2011). Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol, 186, 430-5. https://doi.org/10.1016/j.juro.2011.03.113
  34. Iimura Y, Saito K, Fujii Y, et al (2009). Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol, 181, 1004-12;discussion 12. https://doi.org/10.1016/j.juro.2008.10.156
  35. Ishioka J, Saito K, Sakura M, et al (2012). Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis. Br J Cancer, 107, 1031-6. https://doi.org/10.1038/bjc.2012.254
  36. Ito K, Asano T, Yoshii H, et al (2006). Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol, 13, 1365-70. https://doi.org/10.1111/j.1442-2042.2006.01563.x
  37. Ito M, Saito K, Yasuda Y, et al (2011). Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology, 78, 1131-5. https://doi.org/10.1016/j.urology.2011.07.1416
  38. Jagdev SP, Gregory W, Vasudev NS, et al (2010). Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer, 103, 1649-56. https://doi.org/10.1038/sj.bjc.6605973
  39. Karakiewicz PI, Hutterer GC, Trinh QD, et al (2007). C-reactive protein is an informative predictor of renal cell carcinomaspecific mortality: a European study of 313 patients. Cancer, 110, 1241-7. https://doi.org/10.1002/cncr.22896
  40. Kawata N, Nagane Y, Yamaguchi K, et al (2008). How do symptoms have an impact on the prognosis of renal cell carcinoma? Int J Urol, 15, 299-303. https://doi.org/10.1111/j.1442-2042.2008.01990.x
  41. Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM (2013). Association between C-reactive protein and risk of cancer: a metaanalysis of prospective cohort studies. Asian Pac J Cancer Prev, 14, 243-8. https://doi.org/10.7314/APJCP.2013.14.1.243
  42. Falkensammer CE, Thurnher M, Leonhartsberger N and Ramoner R (2011). C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int, 107, 1893-8. https://doi.org/10.1111/j.1464-410X.2010.09817.x
  43. Fujita T, Iwamura M, Ishii D, et al (2012). C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol, 19, 908-13. https://doi.org/10.1111/j.1442-2042.2012.03071.x
  44. Gakis G, Todenhofer T, Renninger M, et al (2011). Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int, 108, 1800-5. https://doi.org/10.1111/j.1464-410X.2011.10234.x
  45. Hall WA, Nickleach DC, Master VA, et al (2013). The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate. Cancer, 119, 3272-9. https://doi.org/10.1002/cncr.28185
  46. Hayes DF, Isaacs C and Stearns V (2001). Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia, 6, 375-92. https://doi.org/10.1023/A:1014778713034
  47. Hilmy M, Bartlett JM, Underwood MA and McMillan DC (2005). The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer, 92, 625-7. https://doi.org/10.1038/sj.bjc.6602406
  48. Hilmy M, Campbell R, Bartlett JM, et al (2006). The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer, 95, 1234-8. https://doi.org/10.1038/sj.bjc.6603415
  49. Bromwich E, McMillan DC, Lamb GW, et al (2004). The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer, 91, 1236-8. https://doi.org/10.1038/sj.bjc.6602152
  50. Atzpodien J, Royston P, Wandert T, et al (2003). Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer, 88, 348-53. https://doi.org/10.1038/sj.bjc.6600768
  51. Bedke J, Chun FK, Merseburger A, et al (2012). Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int, 110, 771-7. https://doi.org/10.1111/j.1464-410X.2012.11327.x
  52. Beer TM, Lalani AS, Lee S, et al (2008). C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer, 112, 2377-83. https://doi.org/10.1002/cncr.23461
  53. Casamassima A, Picciariello M, Quaranta M, et al (2005). C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol, 173, 52-5. https://doi.org/10.1097/01.ju.0000146713.50673.e5
  54. Cho DS, Kim SJ, Lee SH, et al (2011). Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol, 52, 104-9. https://doi.org/10.4111/kju.2011.52.2.104
  55. Colotta F, Allavena P, Sica A, et al (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 30, 1073-81. https://doi.org/10.1093/carcin/bgp127
  56. de Martino M, Klatte T, Seemann C, et al (2013). Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). BJU Int, 111, 348-53. https://doi.org/10.1111/bju.12067

Cited by

  1. Prognostic Significance of the Peripheral Blood Absolute Monocyte Count in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma Receiving Systemic Chemotherapy vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6387
  2. Albumin-globulin Ratio for Prediction of Long-term Mortality in Lung Adenocarcinoma Patients vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6449
  3. Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8075
  4. Prognostic Value and Clinicopathology Significance of MicroRNA-200c Expression in Cancer: A Meta-Analysis vol.10, pp.6, 2015, https://doi.org/10.1371/journal.pone.0128642
  5. Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5687
  6. The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis vol.22, pp.5, 2017, https://doi.org/10.1007/s10147-017-1171-5
  7. Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy vol.94, pp.42, 2015, https://doi.org/10.1097/MD.0000000000001861
  8. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy vol.118, pp.6, 2018, https://doi.org/10.1038/bjc.2017.467
  9. Can preoperative neutrophil lymphocyte ratio predict malignancy in patients undergoing partial nephrectomy because of renal mass? vol.44, pp.3, 2018, https://doi.org/10.1590/s1677-5538.ibju.2017.0225